Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor

Overview

Journal Cancer Discov

Specialty Oncology

Date 2022 Mar 7

PMID 35254416

Authors

Holly K Koblish

Liangxing Wu

Liang-Chuan S Wang

Phillip C C Liu

Richard Wynn

Jonathan Rios-Doria

Susan Spitz

Hao Liu

Alla Volgina

Nina Zolotarjova

Kanishk Kapilashrami

Elham Behshad

Maryanne Covington

Yan-Ou Yang

Jingwei Li

Sharon Diamond

Maxim Soloviev

Kevin OHayer

Stephen Rubin

Chrysi Kanellopoulou

Gengjie Yang

Mark Rupar

Darlise DiMatteo

Luping Lin

Christina Stevens

Yue Zhang

Pramod Thekkat

Ryan Geschwindt

Cindy Marando

Swamy Yeleswaram

Jeff Jackson

Peggy Scherle

Reid Huber

Wenqing Yao

Gregory Hollis

Affiliations

Soon will be listed here.

Abstract

Significance: We have identified a potent small-molecule inhibitor of PD-L1, INCB086550, which has biological properties similar to PD-L1/PD-1 monoclonal antibodies and may represent an alternative to antibody therapy. Preliminary clinical data in patients demonstrated increased immune activation and tumor growth control, which support continued clinical evaluation of this approach. See related commentary by Capparelli and Aplin, p. 1413. This article is highlighted in the In This Issue feature, p. 1397.

Citing Articles

A Comparative Molecular Dynamics Study of Food-Derived Compounds as PD-L1 Inhibitors: Insights Across Six Flavonoid Subgroups.

Jiang D, Kwon H, Kwon O, Choi Y Molecules. 2025; 30(4).

PMID: 40005217 PMC: 11858612. DOI: 10.3390/molecules30040907.

Antitumor Activity of the PD-1/PD-L1 Inhibitor SCL-1 in Various Mouse Tumor Models.

Ashizawa T, Iizuka A, Kanematsu A, Ando T, Maeda C, Miyata H In Vivo. 2024; 39(1):80-95.

PMID: 39740910 PMC: 11705142. DOI: 10.21873/invivo.13805.

Tumor-specific delivery of clickable inhibitor for PD-L1 degradation and mitigating resistance of radioimmunotherapy.

Hou B, Ye J, Huang L, Cheng W, Chen F, Zhou H Sci Adv. 2024; 10(46):eadq3940.

PMID: 39546592 PMC: 11567003. DOI: 10.1126/sciadv.adq3940.

-driven identification of Pranlukast as a Stabilizer of PD-L1 Homodimers.

Cordova-Bahena L, Landero-Marin C, Flores-Hernandez X, Alvarez-Coronel L, Jimenez-Uribe A, Salinas-Jazmin N Anticancer Agents Med Chem. 2024; 25(3):179-193.

PMID: 39411933 DOI: 10.2174/0118715206303675241009104647.

Miniprotein engineering for inhibition of PD-1/PD-L1 interaction.

Ciesiolkiewicz A, Lizandra Perez J, Skalniak L, Nocen P, Berlicki L Protein Sci. 2024; 33(8):e5106.

PMID: 39012010 PMC: 11250529. DOI: 10.1002/pro.5106.

References

Zhou Q, Xiao H, Liu Y, Peng Y, Hong Y, Yagita H . Blockade of programmed death-1 pathway rescues the effector function of tumor-infiltrating T cells and enhances the antitumor efficacy of lentivector immunization. J Immunol. 2010; 185(9):5082-92. PMC: 3077721. DOI: 10.4049/jimmunol.1001821. View

Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N . Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 2002; 99(19):12293-7. PMC: 129438. DOI: 10.1073/pnas.192461099. View

Postow M, Callahan M, Wolchok J . Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol. 2015; 33(17):1974-82. PMC: 4980573. DOI: 10.1200/JCO.2014.59.4358. View

Zhou J, Mahoney K, Giobbie-Hurder A, Zhao F, Lee S, Liao X . Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade. Cancer Immunol Res. 2017; 5(6):480-492. PMC: 5642913. DOI: 10.1158/2326-6066.CIR-16-0329. View

Tumeh P, Harview C, Yearley J, Shintaku I, Taylor E, Robert L . PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014; 515(7528):568-71. PMC: 4246418. DOI: 10.1038/nature13954. View

Pillai R, Behera M, Owonikoko T, Kamphorst A, Pakkala S, Belani C . Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature. Cancer. 2017; 124(2):271-277. PMC: 5761314. DOI: 10.1002/cncr.31043. View

Beatty G, Gladney W . Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res. 2014; 21(4):687-92. PMC: 4334715. DOI: 10.1158/1078-0432.CCR-14-1860. View

Jiang X, Wang J, Deng X, Xiong F, Ge J, Xiang B . Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol Cancer. 2019; 18(1):10. PMC: 6332843. DOI: 10.1186/s12943-018-0928-4. View

Kolberg L, Raudvere U, Kuzmin I, Vilo J, Peterson H . gprofiler2 -- an R package for gene list functional enrichment analysis and namespace conversion toolset g:Profiler. F1000Res. 2021; 9. PMC: 7859841. DOI: 10.12688/f1000research.24956.2. View

10.

Rios-Doria J, Stevens C, Maddage C, Lasky K, Koblish H . Characterization of human cancer xenografts in humanized mice. J Immunother Cancer. 2020; 8(1). PMC: 7174072. DOI: 10.1136/jitc-2019-000416. View

11.

Riaz N, Havel J, Makarov V, Desrichard A, Urba W, Sims J . Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell. 2017; 171(4):934-949.e16. PMC: 5685550. DOI: 10.1016/j.cell.2017.09.028. View

12.

Gao Y, Nihira N, Bu X, Chu C, Zhang J, Kolodziejczyk A . Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy. Nat Cell Biol. 2020; 22(9):1064-1075. PMC: 7484128. DOI: 10.1038/s41556-020-0562-4. View

13.

Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman D . IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017; 127(8):2930-2940. PMC: 5531419. DOI: 10.1172/JCI91190. View

14.

Park J, Thi E, Carpio V, Bi Y, Cole A, Dorsey B . Checkpoint inhibition through small molecule-induced internalization of programmed death-ligand 1. Nat Commun. 2021; 12(1):1222. PMC: 7900207. DOI: 10.1038/s41467-021-21410-1. View

15.

Gorbachev A, Kobayashi H, Kudo D, Tannenbaum C, Finke J, Shu S . CXC chemokine ligand 9/monokine induced by IFN-gamma production by tumor cells is critical for T cell-mediated suppression of cutaneous tumors. J Immunol. 2007; 178(4):2278-86. DOI: 10.4049/jimmunol.178.4.2278. View

16.

Guzik K, Tomala M, Muszak D, Konieczny M, Hec A, Blaszkiewicz U . Development of the Inhibitors that Target the PD-1/PD-L1 Interaction-A Brief Look at Progress on Small Molecules, Peptides and Macrocycles. Molecules. 2019; 24(11). PMC: 6600339. DOI: 10.3390/molecules24112071. View

17.

Conner K, Devanaboyina S, Thomas V, Rock D . The biodistribution of therapeutic proteins: Mechanism, implications for pharmacokinetics, and methods of evaluation. Pharmacol Ther. 2020; 212:107574. DOI: 10.1016/j.pharmthera.2020.107574. View

18.

Akinleye A, Rasool Z . Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. J Hematol Oncol. 2019; 12(1):92. PMC: 6729004. DOI: 10.1186/s13045-019-0779-5. View

19.

Blank C, Kuball J, Voelkl S, Wiendl H, Becker B, Walter B . Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer. 2006; 119(2):317-27. DOI: 10.1002/ijc.21775. View

20.

Acurcio R, Scomparin A, Conniot J, Salvador J, Satchi-Fainaro R, Florindo H . Structure-Function Analysis of Immune Checkpoint Receptors to Guide Emerging Anticancer Immunotherapy. J Med Chem. 2018; 61(24):10957-10975. DOI: 10.1021/acs.jmedchem.8b00541. View